Given that previous studies have demonstrated the clinical utility of AR antagonists in both primary and metastatic PCa [99], especially Enzalutamide [100], our observation may provide a new insight into developing therapeutic strategy by inhibiting GATA2, TGFβ/SMAD4 and AR signaling together in PCa. The gene discussed is SMAD4; the disease is posterior cortical atrophy.